University of Ioannina
The effect of hypolipidaemic treatment on oxidized phospholipids of lipoprotein (a)
Abstract
dc:descriptionAim: The evaluation of the effect of lipid-lowering treatment on lipidemic, OxPLs levels and IgG/IgM apoB-IC and IgG/IgM anti-MDA-mimotope in individuals with elevated Lp(a) concentrations. Material and methods: A prospective study including 70 patients with dyslipidemia and elevated Lp(a) levels (≥75 nmol/L) attending a Lipid Clinic in Greece. Subjects were allocated to the following therapies according to the national guidelines for cholesterol management: high-intensity statin monotherapy (n=28), ezetimibe added to high-intensity statin (n=31), and PCSK9 inhibitor added to high-intensity statin plus ezetimibe (n=11). Follow-up duration was 3 months. Results: Mean age was 51 ± 15 years, 40% were male, 39% were diagnosed with HeFH, 16% with ASCVD, while 36%, 33% and 15% were at very high, high, and moderate cardiovascular risk, respectively. All interventions significantly reduced apoB-100, TC and LDL-C, but only add-on PCSK9 inhibitor group significantly reduced Lp(a) levels (add-on PCSK9 inhibitor: -43.1% vs add-on ezetimibe: +15.3% vs high-intensity statin: +5.5%, p < 0.05). Patients in the add-on PCSK9 inhibitor group achieved the highest rates of LDL-C reductions (add-on PCSK9 inhibitor: -55% vs add-on ezetimibe: -22% vs high-intensity statin: -43%). No significant effect on glycemic profile across treatment groups was noted. OxPL-apoB and OxPL-apo(a) significantly increased, while OxPL-PLG significantly decreased with both high-intensity statin monotherapy and add-on ezetimibe group. Add-on PCSK9 inhibitor group treatment was associated with no significant changes in OxPL-apoB, OxPL-apo(a) and OxPL-PLG levels. Significant reductions in IgG apoB-IC levels were observed following treatment with all regimens (by 18.3%, 17.5% and 25.5%, respectively, all p < 0.05). No significant changes in IgM apoB-IC, or IgG and IgM anti-MDA-mimotope levels were observed in any treatment group. Conclusions: Add-on PCSK9 inhibitors were associated with the highest rates of LDL-C target achievement compared with high-intensity statin and add-on ezetimibe in high-risk patients with elevated Lp(a) and were the only class to significantly lower Lp(a) levels. In addition, both high-intensity statin and add-on ezetimibe significantly increased OxPL-apoB and OxPL-apo(a) levels, while significantly decreased OxPL-PLG levels. Add-on PCSK9 inhibitors had no significant effect on OxPLs levels.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koutsogianni, Amalia Despoina
- Κουτσογιάννη, Αμαλία-Δέσποινα
Subjects
dc:subject × 8Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61908